Is Abbott Wavering Over Alere?
This article was originally published in Clinica
A non-committal response from Abbott Labs CEO Miles White about the progress of the company’s proposed acquisition of Alere, which is in the midst of a federal investigation over potentially corrupt sales practices abroad, has raised doubts about the $5.8bn transaction. White’s refusal to reaffirm the diagnostic giant’s commitment to the deal slightly eclipsed the positive financial figures it posted for the first quarter this year.
Register for our free email digests: